The FDA panel will review seven peptides and decide if they should be added to a list of substances that can be safely produced by compounding pharmacies.

A FDA advisory committee will review evidence surrounding peptides. Experts are concerned there is a paucity of evidence to back their approval for legal compounding.

With an FDA panel expected to recommend legal production of as many as seven peptides this week, compounding pharmacies and telehealth companies are preparing for the coming…